Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Jason Gill.

Newcastle AuthorsTitleYearFull text
Dr Tarek Mamdouh Abdelghany
Shireen Hedya
Carol De Santis
Dr Jason Gill
Professor Matthew Wright
et al.
Potential for cardiac toxicity with methylimidazolium ionic liquids2023
Dr Rachael Redgrave
Dr Emily Dookun
Laura Booth
Dr Maria Camacho Encina
Dr Omowumi Folaranmi
et al.
Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction2023
Dr Rachael Redgrave
Dr Maria Camacho Encina
Dr Simon Tual-Chalot
Dr Omowumi Folaranmi
Dr Carmen Martin-Ruiz
et al.
The senescence-associated secretory phenotype as a biomarker for age-related myocardial remodelling and cardiovascular disease2023
Dr Simon Findlay
Dr Jason Gill
Baseline blood pressure and development of cardiotoxicity in patients treated with anthracyclines: A systematic review2022
Dr Alistair Brown
Alaa Aljohani
Fatimah Alsalem
Dr Jason Gill
Dr Jon Sellars
et al.
Identification of Substituted Amino Acid Hydrazides as Novel Anti-Tubercular Agents, Using a Scaffold Hopping Approach2020
Dr Simon Findlay
Dr Jason Gill
Professor Ruth Plummer
Carol De Santis
Dr Chris Plummer
et al.
Chronic cardiovascular toxicity in the older oncology patient population2019
Dr Jason Gill
Collaboration, Competition and Publication in Toxicology: views of British Toxicology Society Members2019
Dr Rachel Oldershaw
Dr Andrew Owens
Rachel Telfer-Sutherland
Martin Linney
Rachel Liddle
et al.
Human Cardiac-Mesenchymal Stem Cell-Like Cells, a Novel Cell Population with Therapeutic Potential2019
Dr Alistair Brown
Ahmed Aljohani
Dr Jason Gill
Dr Jon Sellars
Identification of novel benzoxa-[2,1,3]-diazole substituted amino acid hydrazides as potential anti-tubercular agents2019
Dr Jason Gill
Trichostatin A blocks aldosterone-induced Na+ Transport and control of serum- and gulcocorticoid-inducible kinase 1 in cortical collecting duct cells2019
Dr Jason Gill
Kimberly Rockley
Carol De Santis
Asma Mohamed
Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics2019
Professor Adam Todd
Dr Jason Gill
Anticancer Therapeutics: From Drug Discovery to Clinical Applications2018
Dr Jason Gill
Aldosterone-induced Na+ Absorption is Regulated by Protein Acetylation in a Cellular Model of the Cortical Collecting Duct2017
Kimberly Rockley
Dr Jason Gill
Characterisation of Novel Molecular Mechanisms Involved in Anthracycline-Induced Cardiotoxicity2017
Dr Jonathan Harburn
Dr Jason Gill
Rationalized Computer-Aided design of Matrix Metalloprotease-Selective Prodrugs2017
Dr Jason Gill
Anticancer RuII and RhIII Piano-Stool Complexes that are Histone Deacetylase Inhibitors2016
Kimberly Rockley
Dr Gavin Richardson
Dr Jason Gill
Characterisation of novel molecular mechanisms involved in anthracycline-induced cardiotoxicity2016
Hannah Bows
Dr Jason Gill
Integration of pharmacogenetic principles as a core thread in the undergraduate pharmacy curriculum2016
Dr Jason Gill
Oncology Activity2016
Dr Jason Gill
Kimberly Rockley
Pyridylphosphinate Metal Complexes: Synthesis, Structural Characterisation and Biological Activity2016
Dr Jason Gill
Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy2014
Dr Jason Gill
MT-MMP cleavage profiling using rapid endopeptidase profiling library (REPLi)2014
Dr Jason Gill
The Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity2014
Dr Jason Gill
Antitumour activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder2013
Dr Anja Krippner-Heidenreich
Dr Jason Gill
Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity2008